感染症治療薬の世界市場レポート 2025年

感染症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で1,965億米ドルに成長します。予測期間の成長は、投資の増加、臨床試験研究の拡大、臨床試験数の増加、感染症予防への注目の高まり、早期診断に関する意識の高まり、認知度の向上、資金調達などに起因すると考えられます。予測期間における主な動向としては、パートナーシップ、製品承認、投資、治療薬の研究開発などが挙げられます。

感染症の流行増加は感染症治療薬市場の成長を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫、プリオンなどの有害な微生物によって引き起こされる病気です。これらの疾患の増加は、気候変動、環境破壊、抗菌剤耐性、免疫システムの弱体化、人間と動物の相互作用の増大、生態系の不均衡などの要因に起因しています。感染症治療薬は、感染症の治療、罹患率と死亡率の低下、地域社会内および集団間での感染症の蔓延抑制に不可欠なものです。例えば、2023年11月、米国の政府機関である疾病対策予防センター（Centers for Disease Control and Prevention）は、2022年に米国で8,331人の結核患者が発生し、発生率は人口10万人当たり2.5人であったと報告しました。これは2021年と比較して、症例数が5.9％増加し、罹患率が5.5％上昇したことを意味します。したがって、感染症の蔓延が感染症治療薬の需要を牽引しています。

感染症治療薬市場の主なプレーヤーは、より効果的な治療法の開発、抗菌薬耐性への対処、製品ポートフォリオの拡大、新興感染症の脅威への対処のために、感染症治療薬への戦略的な投資を行っています。こうした投資は、患者の転帰を改善し、アンメット・メディカル・ニーズを満たし、感染症の制御と管理に向けた世界の公衆衛生の取り組みに貢献することを目的としています。例えば、英国のヘルスケア企業GSKは2022年6月、低所得国の感染症に積極的に対処するため、10億英ポンド（10億9,000万米ドル）の投資を発表しました。このイニシアチブは、これらの地域に不釣り合いな影響を及ぼす病気と闘うための研究開発の取り組みを強化することを目的としています。高所得国と低・中所得国との間の医療研究資金と資源の格差は、人々の健康を公平に改善するためのこのような積極的な投資の緊急性を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界感染症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の感染症治療薬市場：成長率分析
• 世界の感染症治療薬市場の実績：規模と成長, 2019-2024
• 世界の感染症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界感染症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の感染症治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• ワクチン
• 世界の感染症治療薬市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 結核
• HIV/エイズ
• インフルエンザ
• 肝炎
• その他の病気
• 世界の感染症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 小売薬局
• 調査機関
• その他のエンドユーザー
• 世界の感染症治療薬市場、薬物の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 抗ウイルス薬
• 抗真菌薬
• 抗寄生虫薬
• その他の治療薬（モノクローナル抗体、免疫調節薬）
• 世界の感染症治療薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• 生弱毒化ワクチン
• サブユニットワクチン
• mRNAワクチン
• DNAワクチン
• トキソイドワクチン

第7章 地域別・国別分析

• 世界の感染症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の感染症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 感染症治療薬市場：競合情勢
• 感染症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific
• AstraZeneca
• Abbott Laboratories
• Novartis International AG
• Danaher Corporation
• GlaxoSmithKline plc
• Gilead Sciences Inc.
• Janssen Pharmaceutical
• Siemens Healthineers
• Moderna Inc.
• Becton
• Dickinson
• and Company
• Regeneron Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 感染症治療薬市場2029：新たな機会を提供する国
• 感染症治療薬市場2029：新たな機会を提供するセグメント
• 感染症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Infectious disease therapeutics encompass a range of treatments and interventions designed to combat illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. The primary goal of infectious disease therapeutics is to either eliminate the infectious agent from the body or to control its replication and spread, thereby alleviating symptoms, preventing complications, and ultimately promoting recovery.

The main types of infectious disease therapeutics include drugs and vaccines. Vaccines are biological preparations that stimulate the immune system to recognize and combat specific infectious agents. These therapeutics are utilized to address various diseases such as tuberculosis, HIV/AIDS, influenza, hepatitis, and others. They are accessed by various end-users including hospitals and clinics, retail pharmacies, research organizations, and others.

The infectious disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides infectious disease therapeutics market statistics, including infectious disease therapeutics industry global market size, regional shares, competitors with an infectious disease therapeutics market share, detailed infectious disease therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the infectious disease therapeutics industry. This infectious disease therapeutics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infectious disease therapeutics market size has grown strongly in recent years. It will grow from $141.08 billion in 2024 to $151.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, increasing incidence of viral diseases, growing awareness about diagnosis, rising demand for efficient and quick diagnostic testing, growing demand for cost-effective generic drugs, growing prevalence of infectious diseases, growing importance of antimicrobial stewardship.

The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $196.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing investments, expansion of clinical trial studies, increasing number of clinical trials, increasing focus on infectious disease prevention, increasing awareness about early diagnosis, growing awareness and funding. Major trends in the forecast period include partnerships, product approvals, investments, and research and developments in therapeutics.

The increasing prevalence of infectious diseases is expected to drive the growth of the infectious disease therapeutics market. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, parasites, or prions. The rise in these diseases is attributed to factors such as climate change, environmental disruptions, antimicrobial resistance, weakened immune systems, greater human-animal interactions, and ecological imbalances. Infectious disease therapeutics are essential in treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases both within communities and across populations. For example, in November 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2022, the United States recorded 8,331 tuberculosis (TB) cases, with an incidence rate of 2.5 per 100,000 people. This represents a 5.9% increase in cases and a 5.5% rise in the incidence rate compared to 2021. Therefore, the growing prevalence of infectious diseases is driving the demand for infectious disease therapeutics.

Key players in the infectious disease therapeutics market are making strategic investments in infectious disease drugs to develop more effective treatments, combat antimicrobial resistance, expand their product portfolios, and address emerging infectious threats. These investments aim to improve patient outcomes, meet unmet medical needs, and contribute to global public health efforts to control and manage infectious diseases. For instance, in June 2022, GSK, a UK-based healthcare company, announced a £1 billion (USD 1.09 billion) investment to proactively address infectious diseases in lower-income countries. This initiative seeks to enhance research and development efforts to combat diseases that disproportionately affect these regions. The disparity in health research funding and resources between high-income and low- and middle-income countries underscores the urgency for such proactive investments to improve population health equitably.

In May 2022, OPKO Health, a US-based healthcare company, completed the acquisition of Modex Therapeutics for $300 million. This acquisition significantly bolstered OPKO's technology foundation and expanded its product pipeline into new therapeutic areas, particularly oncology and infectious diseases. Modex Therapeutics, a US-based biotechnology company, specializes in manufacturing infectious disease therapeutics.

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.

North America was the largest region in the infectious disease therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the infectious disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The infectious disease therapeutics market consists of sales of antibiotics, antivirals, and immunotherapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Infectious Disease Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on infectious disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for infectious disease therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The infectious disease therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Drugs; Vaccines
• 2) By Disease: Tuberculosis; HIV/AIDS; Influenza; Hepatitis; Other Diseases
• 3) By End-User: Hospitals And Clinics; Retail Pharmacies; Research Organizations; Other End Users
• Subsegments:

1) By Drugs - Antibiotics; Antivirals; Antifungals; Antiparasitics; Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines - Inactivated Vaccines; Live Attenuated Vaccines; Subunit Vaccines; Mrna Vaccines; Dna Vaccines; Toxoid Vaccines

• Companies Mentioned: Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.;
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Infectious Disease Therapeutics Market Characteristics

3. Infectious Disease Therapeutics Market Trends And Strategies

4. Infectious Disease Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Infectious Disease Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Infectious Disease Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Infectious Disease Therapeutics Market Growth Rate Analysis
• 5.4. Global Infectious Disease Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Infectious Disease Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Infectious Disease Therapeutics Total Addressable Market (TAM)

6. Infectious Disease Therapeutics Market Segmentation

• 6.1. Global Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Vaccines
• 6.2. Global Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tuberculosis
• HIV/AIDS
• Influenza
• Hepatitis
• Other Diseases
• 6.3. Global Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacies
• Research Organizations
• Other End Users
• 6.4. Global Infectious Disease Therapeutics Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antivirals
• Antifungals
• Antiparasitics
• Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)
• 6.5. Global Infectious Disease Therapeutics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccines
• Live Attenuated Vaccines
• Subunit Vaccines
• mRNA Vaccines
• DNA Vaccines
• Toxoid Vaccines

7. Infectious Disease Therapeutics Market Regional And Country Analysis

• 7.1. Global Infectious Disease Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Infectious Disease Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Infectious Disease Therapeutics Market

• 8.1. Asia-Pacific Infectious Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Infectious Disease Therapeutics Market

• 9.1. China Infectious Disease Therapeutics Market Overview
• 9.2. China Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Infectious Disease Therapeutics Market

• 10.1. India Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Infectious Disease Therapeutics Market

• 11.1. Japan Infectious Disease Therapeutics Market Overview
• 11.2. Japan Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Infectious Disease Therapeutics Market

• 12.1. Australia Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Infectious Disease Therapeutics Market

• 13.1. Indonesia Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Infectious Disease Therapeutics Market

• 14.1. South Korea Infectious Disease Therapeutics Market Overview
• 14.2. South Korea Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Infectious Disease Therapeutics Market

• 15.1. Western Europe Infectious Disease Therapeutics Market Overview
• 15.2. Western Europe Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Infectious Disease Therapeutics Market

• 16.1. UK Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Infectious Disease Therapeutics Market

• 17.1. Germany Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Infectious Disease Therapeutics Market

• 18.1. France Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Infectious Disease Therapeutics Market

• 19.1. Italy Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Infectious Disease Therapeutics Market

• 20.1. Spain Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Infectious Disease Therapeutics Market

• 21.1. Eastern Europe Infectious Disease Therapeutics Market Overview
• 21.2. Eastern Europe Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Infectious Disease Therapeutics Market

• 22.1. Russia Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Infectious Disease Therapeutics Market

• 23.1. North America Infectious Disease Therapeutics Market Overview
• 23.2. North America Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Infectious Disease Therapeutics Market

• 24.1. USA Infectious Disease Therapeutics Market Overview
• 24.2. USA Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Infectious Disease Therapeutics Market

• 25.1. Canada Infectious Disease Therapeutics Market Overview
• 25.2. Canada Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Infectious Disease Therapeutics Market

• 26.1. South America Infectious Disease Therapeutics Market Overview
• 26.2. South America Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Infectious Disease Therapeutics Market

• 27.1. Brazil Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Infectious Disease Therapeutics Market

• 28.1. Middle East Infectious Disease Therapeutics Market Overview
• 28.2. Middle East Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Infectious Disease Therapeutics Market

• 29.1. Africa Infectious Disease Therapeutics Market Overview
• 29.2. Africa Infectious Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Infectious Disease Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Infectious Disease Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Infectious Disease Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Infectious Disease Therapeutics Market Competitive Landscape
• 30.2. Infectious Disease Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Infectious Disease Therapeutics Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific
• 31.2. AstraZeneca
• 31.3. Abbott Laboratories
• 31.4. Novartis International AG
• 31.5. Danaher Corporation
• 31.6. GlaxoSmithKline plc
• 31.7. Gilead Sciences Inc.
• 31.8. Janssen Pharmaceutical
• 31.9. Siemens Healthineers
• 31.10. Moderna Inc.
• 31.11. Becton
• 31.12. Dickinson
• 31.13. and Company
• 31.14. Regeneron Pharmaceuticals Inc.
• 31.15. Boehringer Ingelheim GmbH

32. Global Infectious Disease Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Infectious Disease Therapeutics Market

34. Recent Developments In The Infectious Disease Therapeutics Market

35. Infectious Disease Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Infectious Disease Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Infectious Disease Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Infectious Disease Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer